Scholarlink

<p>The optimal anesthetic regimen for acute ischemic stroke (AIS) patients undergoing endovascular thrombectomy (EVT) remains debated. This randomized, double-blind, controlled trial compared the impact of remimazolam versus propofol on intraoperative hemodynamics in this setting. Seventy-four AIS patients were randomly assigned to receive either remimazolam-based or propofol-based general anesthesia. The incidence of intraoperative hypotension was the primary outcome. Vasopressor requirement, recovery times, and neurological outcomes were also assessed. Although the incidence of hypotension during anesthesia induction was comparable between the groups (75.68% vs. 70.27%, <i>p</i> = 0.601), it was significantly lower in the remimazolam group than in the propofol group during anesthesia maintenance (35.14% vs. 86.49%, <i>p</i> &lt; 0.001). The remimazolam group also required significantly less vasopressor and exhibited a smaller maximum decrease in MAP (42 (35, 54) mmHg vs. 56 (47, 64) mmHg, <i>p</i> &lt; 0.001). While not statistically significant, favorable trends were observed in the remimazolam group for neurological improvement at discharge. In conclusion, for AIS patients undergoing EVT, remimazolam provides superior hemodynamic stability compared to propofol, significantly reducing hypotension during anesthesia maintenance, without compromising recovery.</p><p><b>Trial registration</b>: This study was registered at the Chinese Clinical Trail Registry on 23/10/2023 (Registration number ChiCTR2300076880). </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hemodynamic stability with remimazolam versus propofol for general anesthesia in acute ischemic stroke thrombectomy: a randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月16日

查看全文
  • Lijuan Fu,
  • Lan Lan,
  • Xuemeng Chen,
  • Wencai Jiang,
  • Ru Yu,
  • Xiaojuan Huang,
  • Shu Liu,
  • Leqiang Xia,
  • Yukai Zhou,
  • Xianjie Zhang,
  • Rui Zhou

摘要

The optimal anesthetic regimen for acute ischemic stroke (AIS) patients undergoing endovascular thrombectomy (EVT) remains debated. This randomized, double-blind, controlled trial compared the impact of remimazolam versus propofol on intraoperative hemodynamics in this setting. Seventy-four AIS patients were randomly assigned to receive either remimazolam-based or propofol-based general anesthesia. The incidence of intraoperative hypotension was the primary outcome. Vasopressor requirement, recovery times, and neurological outcomes were also assessed. Although the incidence of hypotension during anesthesia induction was comparable between the groups (75.68% vs. 70.27%, p = 0.601), it was significantly lower in the remimazolam group than in the propofol group during anesthesia maintenance (35.14% vs. 86.49%, p < 0.001). The remimazolam group also required significantly less vasopressor and exhibited a smaller maximum decrease in MAP (42 (35, 54) mmHg vs. 56 (47, 64) mmHg, p < 0.001). While not statistically significant, favorable trends were observed in the remimazolam group for neurological improvement at discharge. In conclusion, for AIS patients undergoing EVT, remimazolam provides superior hemodynamic stability compared to propofol, significantly reducing hypotension during anesthesia maintenance, without compromising recovery.

Trial registration: This study was registered at the Chinese Clinical Trail Registry on 23/10/2023 (Registration number ChiCTR2300076880).